documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
107 rows where docket_id = "FDA-2007-D-0369" and posted_year = 2022 sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, comment_end_date, last_modified, open_for_comment, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2007-D-0369-0743 | FDA | None FDA-2007-D-0369 | Request for Extension from King & Spalding | Other | Request for Extension | 2022-12-13T05:00:00Z | 2022 | 12 | 2022-12-13T05:00:00Z | 2022-12-13T19:02:41Z | 0 | 0 | 090000648553435b | ||
| FDA-2007-D-0369-0699 | FDA | None FDA-2007-D-0369 | PSG_019726 - Draft Guidance on Goserelin acetate | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-07T00:43:16Z | 1 | 0 | 09000064854d1eb8 | |
| FDA-2007-D-0369-0698 | FDA | None FDA-2007-D-0369 | PSG_019488 - Draft Guidance on Nicardipine Hydrochloride | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-07T00:43:16Z | 1 | 0 | 09000064854d1eb6 | |
| FDA-2007-D-0369-0711 | FDA | None FDA-2007-D-0369 | PSG_021526 - Draft Guidance on Ranolazine | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:28Z | 1 | 0 | 09000064854d2041 | |
| FDA-2007-D-0369-0721 | FDA | None FDA-2007-D-0369 | PSG_207962 - Draft Guidance on Lidocaine | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:31Z | 1 | 0 | 09000064854d2065 | |
| FDA-2007-D-0369-0718 | FDA | None FDA-2007-D-0369 | PSG_203791 - Draft Guidance on Acyclovir | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:29Z | 1 | 0 | 09000064854d2051 | |
| FDA-2007-D-0369-0726 | FDA | None FDA-2007-D-0369 | PSG_211172 - Draft Guidance on Inotersen Sodium | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:33Z | 1 | 0 | 09000064854d207f | |
| FDA-2007-D-0369-0704 | FDA | None FDA-2007-D-0369 | PSG_020701 - Draft Guidance on Progesterone | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-07T00:43:17Z | 1 | 0 | 09000064854d1f74 | |
| FDA-2007-D-0369-0700 | FDA | None FDA-2007-D-0369 | PSG_020080-Autoinj - Draft Guidance on Sumatriptan Succinate | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-07T00:43:17Z | 1 | 0 | 09000064854d1eba | |
| FDA-2007-D-0369-0732 | FDA | None FDA-2007-D-0369 | PSG_213716 - Draft Guidance on Voclosporin | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:31Z | 1 | 0 | 09000064854d206b | |
| FDA-2007-D-0369-0710 | FDA | None FDA-2007-D-0369 | PSG_021361 - Draft Guidance on Rifaximin | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:29Z | 1 | 0 | 09000064854d2055 | |
| FDA-2007-D-0369-0722 | FDA | None FDA-2007-D-0369 | PSG_208090 - Draft Guidance on Oxycodone | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:30Z | 1 | 0 | 09000064854d205d | |
| FDA-2007-D-0369-0737 | FDA | None FDA-2007-D-0369 | PSG_214200 - Draft Guidance on Trilaciclib Dihydrochloride | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:32Z | 1 | 0 | 09000064854d2079 | |
| FDA-2007-D-0369-0723 | FDA | None FDA-2007-D-0369 | PSG_208843 - Draft Guidance on Hydroxyurea | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:29Z | 1 | 0 | 09000064854d204f | |
| FDA-2007-D-0369-0740 | FDA | None FDA-2007-D-0369 | PSG_215712 - Draft Guidance on Mometasone Furoate | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:30Z | 1 | 0 | 09000064854d2063 | |
| FDA-2007-D-0369-0709 | FDA | None FDA-2007-D-0369 | PSG_021066 - Draft Guidance on Ketotifen fumarate | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:28Z | 1 | 0 | 09000064854d203b | |
| FDA-2007-D-0369-0729 | FDA | None FDA-2007-D-0369 | PSG_213135 - Draft Guidance on Magnesium Sulfate; Potassium Chloride; Sodium Sulfate | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:29Z | 1 | 0 | 09000064854d2057 | |
| FDA-2007-D-0369-0742 | FDA | None FDA-2007-D-0369 | PSG_216018 - Draft Guidance on Ranolazine | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:30Z | 1 | 0 | 09000064854d205b | |
| FDA-2007-D-0369-0739 | FDA | None FDA-2007-D-0369 | PSG_215650 - Draft Guidance on Clindamycin Phosphate | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:31Z | 1 | 0 | 09000064854d206f | |
| FDA-2007-D-0369-0716 | FDA | None FDA-2007-D-0369 | PSG_078878 - Draft Guidance on Omeprazole Magnesium | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:33Z | 1 | 0 | 09000064854d2081 | |
| FDA-2007-D-0369-0714 | FDA | None FDA-2007-D-0369 | PSG_022059 - Draft Guidance on Lapatinib Ditosylate | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:28Z | 1 | 0 | 09000064854d203f | |
| FDA-2007-D-0369-0717 | FDA | None FDA-2007-D-0369 | PSG_202057 - Draft Guidance on Icosapent Ethyl | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:29Z | 1 | 0 | 09000064854d2059 | |
| FDA-2007-D-0369-0728 | FDA | None FDA-2007-D-0369 | PSG_212904 - Draft Guidance on Tivozanib Hydrochloride | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:32Z | 1 | 0 | 09000064854d207d | |
| FDA-2007-D-0369-0702 | FDA | None FDA-2007-D-0369 | PSG_020508 - Draft Guidance on Ammonium Lactate | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:08Z | 1 | 0 | 09000064854d2699 | |
| FDA-2007-D-0369-0712 | FDA | None FDA-2007-D-0369 | PSG_021825 - Draft Guidance on Deferiprone | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:27Z | 1 | 0 | 09000064854d0dd6 | |
| FDA-2007-D-0369-0731 | FDA | None FDA-2007-D-0369 | PSG_213498 - Draft Guidance on Ponesimod | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:28Z | 1 | 0 | 09000064854d2043 | |
| FDA-2007-D-0369-0735 | FDA | None FDA-2007-D-0369 | PSG_214096 - Draft Guidance on Tepotinib Hydrochloride | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:30Z | 1 | 0 | 09000064854d2061 | |
| FDA-2007-D-0369-0695 | FDA | None FDA-2007-D-0369 | PSG_017441 - Draft Guidance on Ferric Oxyhydroxide | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-07T00:43:16Z | 1 | 0 | 09000064854d1d1a | |
| FDA-2007-D-0369-0741 | FDA | None FDA-2007-D-0369 | PSG_215935 - Draft Guidance on Budesonide | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:32Z | 1 | 0 | 09000064854d2073 | |
| FDA-2007-D-0369-0724 | FDA | None FDA-2007-D-0369 | PSG_208845 - Draft Guidance on Triamcinolone Acetonide | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:32Z | 1 | 0 | 09000064854d207b | |
| FDA-2007-D-0369-0705 | FDA | None FDA-2007-D-0369 | PSG_020955 - Draft Guidance on Ferric Oxyhydroxide | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:08Z | 1 | 0 | 09000064854d269e | |
| FDA-2007-D-0369-0727 | FDA | None FDA-2007-D-0369 | PSG_212269 - Draft Guidance on Deferiprone | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:30Z | 1 | 0 | 09000064854d205f | |
| FDA-2007-D-0369-0701 | FDA | None FDA-2007-D-0369 | PSG_020080-Vial - Draft Guidance on Sumatriptan Succinate | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-07T00:43:17Z | 1 | 0 | 09000064854d1ebc | |
| FDA-2007-D-0369-0703 | FDA | None FDA-2007-D-0369 | PSG_020578 - Draft Guidance on Goserelin acetate | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-07T00:43:17Z | 1 | 0 | 09000064854d1f72 | |
| FDA-2007-D-0369-0693 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-02-17T15:36:29Z | 2022-25210 | 0 | 0 | 09000064854d0520 | |
| FDA-2007-D-0369-0713 | FDA | None FDA-2007-D-0369 | PSG_021892 - Draft Guidance on Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:28Z | 1 | 0 | 09000064854d203d | |
| FDA-2007-D-0369-0719 | FDA | None FDA-2007-D-0369 | PSG_206488 - Draft Guidance on Eteplirsen | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:31Z | 1 | 0 | 09000064854d2067 | |
| FDA-2007-D-0369-0734 | FDA | None FDA-2007-D-0369 | PSG_214018 - Draft Guidance on Fosdenopterin Hydrobromide | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:31Z | 1 | 0 | 09000064854d2069 | |
| FDA-2007-D-0369-0725 | FDA | None FDA-2007-D-0369 | PSG_210922 - Draft Guidance on Patisiran Sodium | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:29Z | 1 | 0 | 09000064854d2053 | |
| FDA-2007-D-0369-0736 | FDA | None FDA-2007-D-0369 | PSG_214154 - Draft Guidance on Drospirenone; Estetrol | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:32Z | 1 | 0 | 09000064854d2077 | |
| FDA-2007-D-0369-0696 | FDA | None FDA-2007-D-0369 | PSG_017769 - Draft Guidance on Calcitonin Salmon | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-07T00:43:16Z | 1 | 0 | 09000064854d1d1c | |
| FDA-2007-D-0369-0706 | FDA | None FDA-2007-D-0369 | PSG_020958 - Draft Guidance on Calcium Carbonate; Famotidine; Magnesium Hydroxide | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-07T00:43:17Z | 1 | 0 | 09000064854d1f7a | |
| FDA-2007-D-0369-0707 | FDA | None FDA-2007-D-0369 | PSG_021026 - Draft Guidance on Miconazole Nitrate; White Petrolatum; Zinc Oxide | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-07T00:43:17Z | 1 | 0 | 09000064854d1fed | |
| FDA-2007-D-0369-0715 | FDA | None FDA-2007-D-0369 | PSG_050704 - Draft Guidance on Daunorubicin Citrate | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:28Z | 1 | 0 | 09000064854d0dd8 | |
| FDA-2007-D-0369-0697 | FDA | None FDA-2007-D-0369 | PSG_019155 - Draft Guidance on Ammonium Lactate | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:08Z | 1 | 0 | 09000064854d2544 | |
| FDA-2007-D-0369-0708 | FDA | None FDA-2007-D-0369 | PSG_021065 - Draft Guidance on Ethinyl Estradiol; Norethindrone Acetate | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:27Z | 1 | 0 | 09000064854d0dd4 | |
| FDA-2007-D-0369-0738 | FDA | None FDA-2007-D-0369 | PSG_214383 - Draft Guidance on Melphalan Flufenamide Hydrochloride | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:31Z | 1 | 0 | 09000064854d2071 | |
| FDA-2007-D-0369-0720 | FDA | None FDA-2007-D-0369 | PSG_207924 - Draft Guidance on Baricitinib | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:33Z | 1 | 0 | 09000064854d2083 | |
| FDA-2007-D-0369-0730 | FDA | None FDA-2007-D-0369 | PSG_213138 - Draft Guidance on Fidaxomicin | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:31Z | 1 | 0 | 09000064854d206d | |
| FDA-2007-D-0369-0733 | FDA | None FDA-2007-D-0369 | PSG_213978 - Draft Guidance on Varenicline Tartrate | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:32Z | 1 | 0 | 09000064854d2075 | |
| FDA-2007-D-0369-0694 | FDA | None FDA-2007-D-0369 | PSG_016199 - Draft Guidance on Hydrocortisone | Other | Guidance | 2022-11-18T05:00:00Z | 2022 | 11 | 2022-11-18T05:00:00Z | 2023-04-19T03:59:59Z | 2024-11-12T23:47:08Z | 1 | 0 | 09000064854d2540 | |
| FDA-2007-D-0369-0692 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2022-10-24T04:00:00Z | 2022 | 10 | 2022-10-24T04:00:00Z | 2022-10-24T17:57:15Z | 2022-23015 | 0 | 0 | 090000648544cb99 | |
| FDA-2007-D-0369-0660 | FDA | None FDA-2007-D-0369 | Draft Guidance on Technetium Tc-99m Sodium Pertechnetate Generator- PSG_202158 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:20Z | 1 | 0 | 090000648520a044 | |
| FDA-2007-D-0369-0664 | FDA | None FDA-2007-D-0369 | Draft Guidance on Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate - PSG_210455 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:20Z | 1 | 0 | 090000648520a04c | |
| FDA-2007-D-0369-0670 | FDA | None FDA-2007-D-0369 | Draft Guidance on Acetaminophen; Ibuprofen - PSG_211733 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:21Z | 1 | 0 | 090000648520a058 | |
| FDA-2007-D-0369-0673 | FDA | None FDA-2007-D-0369 | Draft Guidance on Cabotegravir Sodium - PSG_212887 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:22Z | 1 | 0 | 090000648520a05e | |
| FDA-2007-D-0369-0637 | FDA | None FDA-2007-D-0369 | Draft Guidance on Ketoprofen - PSG_018754 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:16Z | 1 | 0 | 09000064852092e0 | |
| FDA-2007-D-0369-0652 | FDA | None FDA-2007-D-0369 | Draft Guidance on Olopatadine Hydrochloride - PSG_021861 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:19Z | 1 | 0 | 090000648520a01b | |
| FDA-2007-D-0369-0658 | FDA | None FDA-2007-D-0369 | Draft Guidance on Dantrolene Sodium - PSG_205579 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:19Z | 1 | 0 | 090000648520a027 | |
| FDA-2007-D-0369-0666 | FDA | None FDA-2007-D-0369 | Draft Guidance on Cytarabine; Daunorubicin - PSG_209401 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:21Z | 1 | 0 | 090000648520a050 | |
| FDA-2007-D-0369-0643 | FDA | None FDA-2007-D-0369 | Draft Guidance on Lamotrigine - PSG_020764 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:17Z | 1 | 0 | 090000648520a009 | |
| FDA-2007-D-0369-0681 | FDA | None FDA-2007-D-0369 | Draft Guidance on Dasiglucagon Hydrochloride - PSG_214231 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:23Z | 1 | 0 | 090000648520a08d | |
| FDA-2007-D-0369-0649 | FDA | None FDA-2007-D-0369 | Draft Guidance on Lanthanum Carbonate - PSG_021468 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:18Z | 1 | 0 | 090000648520a015 | |
| FDA-2007-D-0369-0654 | FDA | None FDA-2007-D-0369 | Draft Guidance on Amoxicillin; Clavulanate Potassium - PSG_050726 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:19Z | 1 | 0 | 090000648520a01f | |
| FDA-2007-D-0369-0674 | FDA | None FDA-2007-D-0369 | Draft Guidance on Vibegron - PSG_213006 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:22Z | 1 | 0 | 090000648520a07f | |
| FDA-2007-D-0369-0680 | FDA | None FDA-2007-D-0369 | Draft Guidance on Azelastine Hydrochloride - PSG_213872 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:23Z | 1 | 0 | 090000648520a08b | |
| FDA-2007-D-0369-0684 | FDA | None FDA-2007-D-0369 | Draft Guidance on Cyclosporine - PSG_214965 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:23Z | 1 | 0 | 090000648520a093 | |
| FDA-2007-D-0369-0640 | FDA | None FDA-2007-D-0369 | Draft Guidance on Medroxyprogesterone Acetate - PSG_012541 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:16Z | 1 | 0 | 090000648520a003 | |
| FDA-2007-D-0369-0663 | FDA | None FDA-2007-D-0369 | Draft Guidance on Meloxicam - PSG_210583 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:20Z | 1 | 0 | 090000648520a04a | |
| FDA-2007-D-0369-0644 | FDA | None FDA-2007-D-0369 | Draft Guidance on Famotidine - PSG_020801 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:17Z | 1 | 0 | 090000648520a00b | |
| FDA-2007-D-0369-0651 | FDA | None FDA-2007-D-0369 | Draft Guidance on Cetirizine Hydrochloride - PSG_021621 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:18Z | 1 | 0 | 090000648520a019 | |
| FDA-2007-D-0369-0657 | FDA | None FDA-2007-D-0369 | Draft Guidance on Ampicillin/Ampicillin Trihydrate - PSG_064082 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:19Z | 1 | 0 | 090000648520a025 | |
| FDA-2007-D-0369-0656 | FDA | None FDA-2007-D-0369 | Draft Guidance on Ethinyl Estradiol; Norethindrone Acetate - PSG_203667 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:19Z | 1 | 0 | 090000648520a023 | |
| FDA-2007-D-0369-0662 | FDA | None FDA-2007-D-0369 | Draft Guidance on Tacrolimus - PSG_210115 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:20Z | 1 | 0 | 090000648520a048 | |
| FDA-2007-D-0369-0672 | FDA | None FDA-2007-D-0369 | Draft Guidance on Nifurtimox - PSG_213464 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:21Z | 1 | 0 | 090000648520a05c | |
| FDA-2007-D-0369-0676 | FDA | None FDA-2007-D-0369 | Draft Guidance on Vericiguat - PSG_214377 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:22Z | 1 | 0 | 090000648520a083 | |
| FDA-2007-D-0369-0668 | FDA | None FDA-2007-D-0369 | Draft Guidance on Upadacitinib - PSG_211675 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:21Z | 1 | 0 | 090000648520a054 | |
| FDA-2007-D-0369-0669 | FDA | None FDA-2007-D-0369 | Draft Guidance on Loteprednol Etabonate - PSG_210933 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:21Z | 1 | 0 | 090000648520a056 | |
| FDA-2007-D-0369-0677 | FDA | None FDA-2007-D-0369 | Draft Guidance on Setmelanotide Acetate - PSG_213793 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:22Z | 1 | 0 | 090000648520a085 | |
| FDA-2007-D-0369-0682 | FDA | None FDA-2007-D-0369 | Draft Guidance on Relugolix - PSG_214621 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:23Z | 1 | 0 | 090000648520a08f | |
| FDA-2007-D-0369-0638 | FDA | None FDA-2007-D-0369 | Draft Guidance on Ibuprofen - PSG_020601 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:16Z | 1 | 0 | 09000064852092e2 | |
| FDA-2007-D-0369-0648 | FDA | None FDA-2007-D-0369 | Draft Guidance on Methylphenidate Hydrochloride - PSG_021475 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:18Z | 1 | 0 | 090000648520a013 | |
| FDA-2007-D-0369-0665 | FDA | None FDA-2007-D-0369 | Draft Guidance on Oxymetazoline Hydrochloride; Tetracaine Hydrochloride - PSG_208032 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:20Z | 1 | 0 | 090000648520a04e | |
| FDA-2007-D-0369-0679 | FDA | None FDA-2007-D-0369 | Draft Guidance on Lonafarnib - PSG_213969 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:23Z | 1 | 0 | 090000648520a089 | |
| FDA-2007-D-0369-0659 | FDA | None FDA-2007-D-0369 | Draft Guidance on Prednisone - PSG_202020 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:20Z | 1 | 0 | 090000648520a042 | |
| FDA-2007-D-0369-0671 | FDA | None FDA-2007-D-0369 | Draft Guidance on Gallium Ga-68 Gozetotide - PSG_212642 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:21Z | 1 | 0 | 090000648520a05a | |
| FDA-2007-D-0369-0639 | FDA | None FDA-2007-D-0369 | Draft Guidance on Medroxyprogesterone Acetate - PSG_020246 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:16Z | 1 | 0 | 090000648520a001 | |
| FDA-2007-D-0369-0641 | FDA | None FDA-2007-D-0369 | Draft Guidance on Carbamazepine - PSG_018281 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:17Z | 1 | 0 | 090000648520a005 | |
| FDA-2007-D-0369-0642 | FDA | None FDA-2007-D-0369 | Draft Guidance on Loperamide Hydrochloride; Simethicone - PSG_020606 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:17Z | 1 | 0 | 090000648520a007 | |
| FDA-2007-D-0369-0653 | FDA | None FDA-2007-D-0369 | Draft Guidance on Etonogestrel - PSG_021529 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:19Z | 1 | 0 | 090000648520a01d | |
| FDA-2007-D-0369-0667 | FDA | None FDA-2007-D-0369 | Draft Guidance on Amphetamine; Amphetamine Aspartate/Dextroamphetamine Sulfate - PSG_210526 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:21Z | 1 | 0 | 090000648520a052 | |
| FDA-2007-D-0369-0678 | FDA | None FDA-2007-D-0369 | Draft Guidance on Berotralstat Hydrochloride - PSG_214094 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:22Z | 1 | 0 | 090000648520a087 | |
| FDA-2007-D-0369-0683 | FDA | None FDA-2007-D-0369 | Draft Guidance on Pafolacianine Sodium - PSG_214907 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:23Z | 1 | 0 | 090000648520a091 | |
| FDA-2007-D-0369-0655 | FDA | None FDA-2007-D-0369 | Draft Guidance on Loratadine - PSG_021891 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:19Z | 1 | 0 | 090000648520a021 | |
| FDA-2007-D-0369-0645 | FDA | None FDA-2007-D-0369 | Draft Guidance on Caspofungin Acetate - PSG_021227 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:17Z | 1 | 0 | 090000648520a00d | |
| FDA-2007-D-0369-0647 | FDA | None FDA-2007-D-0369 | Draft Guidance on Caspofungin Acetate - PSG_021227 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:17Z | 1 | 0 | 090000648520a011 | |
| FDA-2007-D-0369-0661 | FDA | None FDA-2007-D-0369 | Draft Guidance on Doxycycline Hyclate - PSG_050751 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:20Z | 1 | 0 | 090000648520a046 | |
| FDA-2007-D-0369-0636 | FDA | None FDA-2007-D-0369 | Draft Guidance on Azelastine Hydrochloride - PSG_020114 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:16Z | 1 | 0 | 09000064852092de | |
| FDA-2007-D-0369-0646 | FDA | None FDA-2007-D-0369 | Draft Guidance on Nicotine - PSG_020385 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:17Z | 1 | 0 | 090000648520a00f | |
| FDA-2007-D-0369-0675 | FDA | None FDA-2007-D-0369 | Draft Guidance on Mometasone Furoate; Olopatadine Hydrochloride - PSG_211746 | Other | Guidance | 2022-08-05T04:00:00Z | 2022 | 8 | 2022-08-05T04:00:00Z | 2022-10-04T03:59:59Z | 2024-11-07T00:41:22Z | 1 | 0 | 090000648520a081 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;